var data={"title":"Technetium Tc-99m sodium pertechnetate : Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Technetium Tc-99m sodium pertechnetate : Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/383910?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=technetium-tc-99m-sodium-pertechnetate-drug-information\" class=\"drug drug_general\">see &quot;Technetium Tc-99m sodium pertechnetate : Drug information&quot;</a> and <a href=\"topic.htm?path=technetium-tc-99m-sodium-pertechnetate-patient-drug-information\" class=\"drug drug_patient\">see &quot;Technetium Tc-99m sodium pertechnetate : Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7734606\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>TechneLite</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46148041\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Radiopharmaceutical</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46148044\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=technetium-tc-99m-sodium-pertechnetate-drug-information\" class=\"drug drug_general\">see &quot;Technetium Tc-99m sodium pertechnetate : Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Measure dose with appropriate radioactivity calibration system immediately prior to administration. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Thyroid gland imaging:</b> Children and Adolescents: IV: 60 to 80 &micro;Ci/kg (2.2 to 2.96 MBq/kg) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Urinary bladder imaging (direct isotopic cystography):</b> Children and Adolescents: Intracatheter (urethral): 0.5 to 1 mCi (18.5 to 37 MBq)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Nasolacrimal drainage system imaging:</b> Dacryoscintigraphy: Maximum: 100 &micro;Ci (3.7 MBq)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Salivary gland imaging:</b> IV: 1 to 5 mCi (37 to 185 MBq)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Thyroid gland imaging:</b> IV: 1 to 10 mCi (37 to 370 MBq)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Urinary bladder imaging:</b> Intracatheter (urethral): 0.5 to 1 mCi (18.5 to 37 MBq)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <b>Dosing adjustment  in renal impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment  in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46132885\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Generator Column, for elution in producing technetium 99m sodium pertechnetate solution for injection:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">TechneLite: Molybdenum Mo99 1-20 Ci per generator system [available in high or low enriched uranium]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46148046\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Radiopharmaceutical; use appropriate precautions for handling and disposal. Use waterproof gloves and effective radiation shielding when handling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nasolacrimal drainage system imaging: Instill via a micropipette or similar method to ensure dosage accuracy. Instruct patient to blow nose and wash eyes with sterile distilled water or isotonic sodium chloride to minimize radiation dose following procedure.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Urinary bladder and ureters imaging (direct isotopic cystography): Instill via urethral catheter directly into the bladder. After instillation flush catheter with ~200 mL of sterile saline directly into the bladder.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46132917\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store generator at controlled room temperature of 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted between 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Do not use after 12 hours once elution has occurred.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46148042\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Radiopharmaceutical imaging agent used for thyroid gland imaging and urinary bladder imaging (direct isotopic cystography) for the detection of vesico-ureteral reflux (FDA approved in pediatric patients [age not specified] and adults); radiopharmaceutical imaging agent used for nasolacrimal drainage system imaging (dacryoscintigraphy) and salivary gland imaging (FDA approved in adults) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7734604\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Radiopharmaceutical: Use appropriate precaution for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use under supervision of experienced personnel. Should be stored in original lead container or adequate radiation shield.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F44938145\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity:  Anaphylaxis (infrequent)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46132902\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">There are no contraindications listed in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46132915\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Hypersensitivity reaction, including serious signs/symptoms of anaphylaxis and allergic reactions (rash, hives, itching) have been reported. Appropriate equipment and personnel for emergency treatment should be immediately available.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Radiation accumulation: Tc 99m administration contributes to a patient&rsquo;s overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk for cancer. Use the lowest dose necessary for imaging. Risk is greater with pediatric patients due to greater radiosensitivity and longer life expectancy. Ensure safe handling to minimize radiation exposure to the patient and health care providers.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special handling:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Radiopharmaceutical: Use appropriate precautions for handling, disposal, and minimizing exposure to patients and health care personnel. Use only under supervision of individuals with experience/training in the handling of radioactive materials approved by the applicable regulatory authority.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Patients should be adequately hydrated prior to intravenous or intravesicular administration; instruct patients to void immediately after imaging study is complete and then frequently over the next 12 hours to decrease radiation exposure to the bladder. Instruct patients to blow nose and/or wash eyes after ophthalmic administration to decrease dose of radiation absorbed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Radiation exposure: Unintended exposure to molybdenum Mo-99 contributes to overall cumulative radiation dose. Strict adherence to the eluate testing protocol must be followed.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F30151973\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F30151970\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=106989&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46132894\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46132897\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Animal reproduction studies have not been conducted. Technetium Tc 99m can be detected in fetal tissue; the amount depends upon the specific formulation, route of administration, and stage of pregnancy (Adelstein 1999).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In general, the potential for a radiopharmaceutical to cause fetal harm depends on the dose absorbed by the fetus and the stage of pregnancy. High doses of radiopharmaceuticals used for therapeutic procedures are more likely to result in fetal harm. A medically required diagnostic procedure can usually be modified to decrease fetal risk. Elective diagnostic procedures should be delayed until after delivery (Adelstein 1999; ICRP 2000; Parker 2004). Pregnancy status should be determined in women of childbearing potential (Parker 2004). The manufacturer recommends that elective procedures done in women of reproductive potential be conducted within the first few (~10) days following onset of menses.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51129392\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Radioactive diagnostic agent which distributes in the body similarly to the iodide ion, however is not organified in the thyroid (pertechnetate is released from the thyroid unchanged).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46132923\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Pertechnetate concentrates in the gastric mucosa, thyroid gland, salivary glands, and urinary bladder</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Physical half-life: 6.01 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: IV: 3.5 hours (cerebral spinal fluid); 0.25 to 2 hours (thyroid [euthyroid patients])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (27% in 1 day; 31% in 4 days; 34% in 8 days)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46221445\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Ultra TechneKow FM (AT, BE, CZ, ES, FR, IE, NO, PT);</li>\n      <li>Ultra-TechhneKow FM (DK);</li>\n      <li>UltratechneKow FM (HU)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahlgren L, Ivarsson S, Johansson L, et al, &quot;Excretion of Radionuclides in Human Breast Milk After the Administration of Radiopharmaceuticals,&quot;<i> J Nucl Med</i>, 1985, 26(9):1085-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/technetium-tc-99m-sodium-pertechnetate-pediatric-drug-information/abstract-text/4032049/pubmed\" target=\"_blank\" id=\"4032049\">4032049</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Adelstein SJ, &quot;Administered Radionuclides in Pregnancy,&quot; <i>Teratology</i>, 1999, 59(4):236-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/technetium-tc-99m-sodium-pertechnetate-pediatric-drug-information/abstract-text/10331526/pubmed\" target=\"_blank\" id=\"10331526\">10331526</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Radiology (ACR) and Society for Pediatric Radiology (SPR), &quot;ACR-SPR Practice Guideline for the Performance of Adult and Pediatric Renal Scintigraphy,&quot; 2014. Available at http://www.acr.org/~/media/ACR/Documents/PGTS/guidelines/Renal_Scintigraphy.pdf</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Radiology (ACR), Society for Pediatric Radiology (SPR), and Society of Nuclear Medicine (SNM), &quot;ACR-SPR-SNM Practice Guideline for the Performance of Adult and Pediatric Radionuclide Cystography,&quot; 2010. Available at http://snmmi.files.cms-plus.com/docs/Radionuclide_Cystography_1382732076756_9.pdf</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Drytec (technetium tc-99m sodium pertechnetate) [prescribing information]. Arlington Heights, IL: GE Healthcare, Medi-Physics, Inc; January 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Harding LK, Bossuyt S, Pellet C, et al, &quot;Recommendations for Nuclear Medicine Physicians Regarding Breastfeeding Mothers,&quot; <i>Eur J Nucl Med</i>, 1995, 22(5)BP17.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    International Commission on Radiological Protection (ICRP), &quot;Pregnancy and Medical Radiation,&quot; <i>Ann ICRP</i>, 2000, 30(1):iii-viii, 1-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/technetium-tc-99m-sodium-pertechnetate-pediatric-drug-information/abstract-text/11108925/pubmed\" target=\"_blank\" id=\"11108925\">11108925</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kaya M, Ustun F, Gultekin A, et al, &quot;Secretion of Radioactivity in Breast Milk After Tc-99m DTPA Aerosol and Tc-99m MAA Lung Imaging,&quot; <i>Clin Nucl Med</i>, 2001, 26(7):657-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/technetium-tc-99m-sodium-pertechnetate-pediatric-drug-information/abstract-text/11416765/pubmed\" target=\"_blank\" id=\"11416765\">11416765</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mountford PJ and Coakley AJ, &quot;A Review of the Secretion of Radioactivity in Human Breast Milk: Data, Quantitative Analysis and Recommendations,&quot; <i>Nucl Med Commun</i>, 1989, 10(1):15-27.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/technetium-tc-99m-sodium-pertechnetate-pediatric-drug-information/abstract-text/2645546/pubmed\" target=\"_blank\" id=\"2645546\">2645546</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Parker JA, Daube-Witherspoon ME, Graham LS, et al, &quot;Procedure Guideline for General Imaging: 3.0,&quot; Society of Nuclear Medicine, 2004. Available at http://interactive.snm.org/docs/General_Imaging_v3.0.pdf</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rubow S, Klopper J, Wasserman H, et al, &quot;The Excretion of Radiopharmaceuticals in Human Breast Milk: Additional Data and Dosimetry,&quot; <i>Eur J Nucl Med</i>, 1994, 21(2):144-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/technetium-tc-99m-sodium-pertechnetate-pediatric-drug-information/abstract-text/8162938/pubmed\" target=\"_blank\" id=\"8162938\">8162938</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stabin MG and Breitz HB, &quot;Breast Milk Excretion of Radiopharmaceuticals: Mechanisms, Findings, and Radiation Dosimetry,&quot; <i>J Nucl Med</i>, 2000, 41(5):863-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/technetium-tc-99m-sodium-pertechnetate-pediatric-drug-information/abstract-text/10809203/pubmed\" target=\"_blank\" id=\"10809203\">10809203</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    TechneLite (technetium 99m sodium pertechnetate) [prescribing information]. N. Billerica, MA: Lantheus Medical Imaging; February, 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Nuclear Regulatory Commission (USNRC), &quot;Regulatory Guide 8.39. Release of Patients Administered Radioactive Materials,&quot; 1997.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 106989 Version 11.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F7734606\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F46148041\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F46148044\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F46132885\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F46148046\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F46132917\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F46148042\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F7734604\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F44938145\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F46132902\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F46132915\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F30151973\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F30151970\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F46132894\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F46132897\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F51129392\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F46132923\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F46221445\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/106989|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=technetium-tc-99m-sodium-pertechnetate-drug-information\" class=\"drug drug_general\">Technetium Tc-99m sodium pertechnetate : Drug information</a></li><li><a href=\"topic.htm?path=technetium-tc-99m-sodium-pertechnetate-patient-drug-information\" class=\"drug drug_patient\">Technetium Tc-99m sodium pertechnetate : Patient drug information</a></li></ul></div></div>","javascript":null}